Major guidelines recommend lowering systolic blood pressure (SBP) to ,140 mmHg in all hypertensives, but evidence is missing whether this is beneficial in (i) uncomplicated hypertensives, (ii) grade 1 hypertensives, and (iii) elderly hypertensives. Providing this missing evidence is important to justify efforts and costs of aggressive therapy in all hypertensives.
Introduction
A recent document 1 
reappraising the 2007 European Society of
Hypertension-European Society of Cardiology guidelines for management of hypertension 2 points out that the recommendation, common to all major guidelines, 2 -4 to lower systolic blood pressure (SBP) to values ,140 mmHg in all hypertensive patients is not founded on undisputable evidence. Indeed, most trials showing morbidity and mortality benefits by achieving mean SBP values ,140 mmHg were only on patients at high cardiovascular risk, 5 and in no trial of antihypertensive treatment in the elderly was a mean SBP ,140 mmHg achieved in the actively treated group. 5 Therefore, efforts and costs of intense drug therapy to lower SBP ,140 mmHg in millions of uncomplicated or elderly hypertensives are still based on opinion rather than evidence.
In the Felodipine Event Reduction (FEVER) randomized trial, lowering SBP to a mean of 138 mmHg by more active treatment was accompanied by significant 25-35% reductions in cardiovascular outcomes when compared with SBP lowering to a mean of 142 mmHg by less active treatment. 6 However, the FEVER cohort included 42% of hypertensives with previous cardiovascular events and 13% of diabetics, and its results cannot safely be extended to uncomplicated moderate hypertensive patients 1, 5 unless specific subgroup analyses are provided. The FEVER study 6 was of sufficiently large size (9711 patients) and outcome differences between the two treatment arms conspicuous enough (average 28% reduction) to allow separate analyses in different risk groups, and the analyses here reported help clarifying some of the problems the ESH Task Force has found still open: is aiming at SBP ,140 mmHg beneficial in (i) uncomplicated hypertensive patients, (ii) individuals with moderately elevated BP, and (iii) in the elderly?
Methods

Study population and treatment
Details on the FEVER study design and organization have been published. 6 After approval by local Ethics Committees, and obtaining 
Definition of outcomes
Primary outcome was time to first stroke (fatal or non-fatal). Prespecified secondary outcomes were time to: (i) first cardiovascular event (death from cardiovascular disease, non-fatal stroke, non-fatal myocardial infarction, dissecting aortic aneurysm, heart failure requiring additional treatment, percutaneous transluminal coronary angioplasty, or coronary by-pass graft, angioplasty or surgical procedures for peripheral vascular disease, serum creatinine ≥355 mmol/L), (ii) first cardiac event (death from coronary heart disease, including sudden death, non-fatal myocardial infarction, death from heart failure, heart failure requiring additional therapy, percutaneous transluminal coronary angioplasty or coronary by-pass graft); (iii) death from any cause; (iv) death from cardiovascular disease, a composite of death from coronary heart disease, fatal stroke and death from heart failure. All outcomes were validated by an independent Event Adjudicating Committee, blind to randomized treatment. Only validated outcomes were included in the analyses.
Statistical methods
All analyses were performed according to the intention-to-treat principle. Cox regression models were used to assess outcome differences between treatments within any given group, with calculation of hazard ratios (HRs) and their 95% confidence intervals (CIs). Cumulative event rates over time were illustrated by Kaplan-Meier curves. Only time to first event was considered for composite outcomes, but a single patient could have a first event counted in each individual outcome category. Heterogeneity of hazard ratios among groups defined by baseline characteristics was investigated by interaction analyses. All tests were two-sided and the significance level chosen was P , 0.05. Statistical analyses used the SAS System (version 8.2; SAS Institute, Inc., Cary, NC, USA).
Results
On-treatment blood pressures achieved by randomized treatment in various groups of patients
The baseline characteristics of patients in each risk group were presented in a previous paper. 7 In all groups considered, average on-treatment SBP achieved mean values ,140 mmHg in the felodipine arm, whereas SBP mean remained .140 mmHg on placebo. Only in patients with higher SBP at randomization (mean 164.5 mmHg) mean SBP remained .140 mmHg in both treatment arms, whereas in those with lower randomization SBP (mean Target BP in antihypertensive treatment 144.2 mmHg) this decreased to ,140 mmHg in both arms. In all groups, on-treatment DBP averaged ,84 mmHg in the felodipine, and commonly .84 mmHg in the placebo arm (with the exception of subjects with isolated systolic hypertension). In all groups, SBP was lower by 3.7 -6.5 mmHg and DBP by 1.6 -3.1 mmHg in the felodipine arm ( Table 1) .
Effects of randomized treatment on the primary outcome (fatal and non-fatal stroke)
Kaplan -Meier curves with cumulative strokes in patients randomized to felodipine or placebo are illustrated in Figure 1 for the three groups of patients for whom benefits of reducing SBP ,140 mmHg are yet unknown 1, 5 : (i) uncomplicated hypertensives (neither diabetes nor cardiovascular disease); (ii) hypertensives with randomization SBP ,153 mmHg (mean 144/89 mmHg); (iii) elderly hypertensives (mean age 69.5 years). Significant reductions in stroke incidence were observed in these groups. In absolute terms, further lowering of SBP/DBP by a few millimeters of mercury over an average treatment period of 3.3 years led to the prevention of 1.6, 1.1, and 3.8 strokes every 100 patients with uncomplicated hypertension, moderately elevated BP, and elderly hypertension, respectively. In all other groups, both those with and those without a given risk factor or disease, the HRs were consistently below unity, with values between 0.54 and 0.91, i.e. favouring the treatment (felodipine) achieving a lower average SBP. In most of the groups, HRs were statistically significant ( Table 1) . Statistical significance was not achieved in younger patients (mean age 57.6 years), those with baseline cardiovascular disease, smokers, patients with higher cholesterol, and with isolated systolic hypertension. However, interaction analyses indicated that there was no major between-group difference in stroke reduction by lower SBP/DBP values (P always .0.05), except for age (P ¼ 0.005).
Effects of randomized treatment on secondary outcomes Table 2 and Figure 2 illustrate that greater lowering of SBP/DBP was beneficial not only on stroke, but also on secondary outcomes in the elderly, in individuals with moderate blood pressure elevation at randomization and in hypertensives with neither cardiovascular disease nor diabetes (uncomplicated hypertensives), as well as in women. In absolute terms, 2.1, 1.6, and 5.2 cardiovascular events could be prevented over 3.3 years every 100 patients with uncomplicated hypertension, moderate blood pressure elevation, and elderly hypertension, respectively.
In most other groups, HRs for secondary outcomes were consistently below unity: 0. tighter BP control in non-diabetic hypertensives significantly reduced the rate of LVH, but information on hard outcomes was limited by their low number in this small study. In FEVER among the 4850 hypertensives with neither cardiovascular disease nor diabetes incident cardiovascular events were 13.6% in 10 years (16.8% on placebo and 10.7% on felodipine), and SBP/DBP reduction to mean values of 138.1/82.8 mmHg rather than 141.9/85.1 was accompanied by significant 40% reductions in stroke, cardiovascular events, cardiac events, and all cause mortality. We also found that in FEVER achieving mean SBP ,140 mmHg significantly reduced stroke and cardiovascular events in women whose 10-year cardiovascular risk was only 13.9%. Current evidence of benefits of antihypertensive treatment in women is largely based on meta-analyses, 12,13 significant data from individual trials being scanty. Also hypertensives with randomization SBP ,153 mmHg and 10-year cardiovascular risk 13.8% significantly benefited from lowering SBP to a mean of 134.7 mmHg rather than 138.4 mmHg. Because these analyses were deliberately restricted to moderate risk hypertensives, absolute benefits could not be large, but prevention of 1.6 -2.1 cardiovascular events (the majority being strokes) every 100 patients over 3.3 years appears worth aiming at a slightly lower blood pressure by the addition of a small dose of a generic antihypertensive drug, such as 5 mg felodipine. CI, confidence internal; CV, cardiovascular; CVD, cardiovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; HR, hazard ratio; ISH, isolated systolic hypertension; LVH, left ventricular hypertrophy; pt. y, patients years; Rand, randomization; SBP, systolic blood pressure; P, P-value for HR; P ia , P-value for interaction between subgroups.
Elderly hypertensives
In no previous trial of antihypertensive therapy in the elderly did SBP achieve mean values ,140 mmHg, 5 since all studies aimed at ,150 mmHg. 14 -22 Therefore, our finding that in hypertensives aged .65 years (at a mean age similar to that in most previous trials 12 -14,16 -18 ) lowering of SBP by felodipine to a mean just ,140 mmHg (rather than 145 mmHg in the placebo arm) significantly reduced stroke, cardiovascular events, cardiac events, and all death by 40-50% (with prevention of 3.8 strokes and 5.2 cardiovascular events every 100 patients over 3.3 years) is the first evidence in favour of aiming at a SBP ,140 mmHg also in the elderly. Admittedly, the mean SBP achieved on felodipine in the elderly was just ,140 mmHg (139.7 mmHg), but it was definitely lower than mean values achieved in all other trials on the elderly (never ,143 mmHg and often .150 mmHg).
It should be acknowledged that in younger patients (≤65 years) achievement of a mean SBP ,140 mmHg did not significantly reduce any type of event, and that age was the only subgroup in which interaction analyses indicated significant differences between older and younger individuals, at least for stroke and all cardiovascular events (though not for mortality). However, HRs were always lower than unity, and the low cardiovascular risk (less than half that of the elderly) made significance difficult to be reached.
High-risk hypertensives
Doubts were recently raised about the foundation of recommending SBP values ,130 in diabetics or patients with previous cardiovascular events, 1, 5 an issue supported by subsequent publication of the ACCORD trial in diabetics. 23 Even evidence favouring SBP ,140mmHg in these patients is scanty. In diabetics, MicroHOPE 24 reported a 25% reduction in primary outcome by reducing SBP to a mean of 139 rather than 142 mmHg, and ADVANCE a 9% reduction in primary outcome (mostly microvascular events) for a SBP mean of 134 rather than 140 mmHg. 25 Among patients with previous stroke, the benefits of reducing SBP to a mean of 132 rather than 141 mmHg in PROGRESS 26 are counterbalanced by the negative data of PROFESS. 27 Of six placebo-controlled trials on coronary patients, only two showed significant outcome reductions for SBP means of 135 and, respectively, 128 mmHg.
1,5
The often reported opinion that the benefit of antihypertensive therapy is proportionally greater in high-risk patients is not based on direct comparisons in trials, and contrasts with the meta-analysis by Law et al. 28 showing the same proportional reduction in coronary events, and a slightly lower prevention of strokes in subjects with history of vascular disease than in subjects without. Several of our analyses of the FEVER study add information in higher vs. lower risk hypertensives. In diabetic patients, Target BP in antihypertensive treatment we found a significant 44% reduction in strokes with more intense treatment, but a 20% reduction in cardiovascular events and a 7% in cardiac events did not achieve statistical significance, and no change was found in all and cardiovascular deaths. On the other hand, all types of outcomes were significantly reduced in nondiabetics. However, the group of diabetics was relatively small (n ¼ 1241), and all P-values for interactions .0.05. In patients with higher serum cholesterol values more intense BP lowering had similar benefits as in the subgroup with lower cholesterol, except for mortality which was more markedly reduced in the higher cholesterol subgroup. However, FEVER patients with cholesterol .5.7 mmol/L were not found at an increased cardiovascular risk, 7 an observation consistent with epidemiological data from Asia showing that high cholesterol adds little cardiovascular risk, particularly for stroke, at SBP .150 mmHg. 29 Anyway, in FEVER this was not due to the use of statins, which were taken by ,1% of the patients. In the relatively large group of patients with a previous cardiovascular disease (n ¼ 3894), there were significant reductions in all cardiovascular events, cardiac events, all deaths, and cardiovascular deaths. However, with the exception of the elderly, in higher risk groups of FEVER, the relative reduction in cardiovascular events tended to be somewhat lower and absolute event reduction similar to that in lower risk groups (either/neither cardiovascular disease or diabetes 24.7/26.1, men/women 25.9/25.7, with/without LVH 26.2/25.5 cardiovascular events per 1000 patient years).
Strengths and limitations
The strength of the analyses here reported is that FEVER included a large cohort of hypertensives (n ¼ 9711), the number of incident cardiovascular events was high (n ¼ 575), benefit of more intense blood pressure lowering was large (27% outcome reduction) and highly significant (P , 0.002). Furthermore, reports of benefits of lowering SBP to a mean ,140 mmHg are not only based, as frequent in subgroup analyses of trials, on the finding that subgroup HRs are not heterogeneous, even when formal significance is lost. In our analyses, the statement that SBP lowering to a mean ,140 mmHg was beneficial in a given subgroup was based on the fact that statistical significance was achieved. Because of the descriptive values of our analyses, correction for multiple testing was done, but in many cases, e.g. in elderly patients and in those without any previous cardiovascular disease, HRs for stroke had P-values ,0.001. Limitations are those inherent in subgroup or post hoc analyses, although gender, age, diabetes, and cardiovascular disease were used to stratify randomization, and therefore randomization was preserved and most covariates were satisfactorily controlled in groups based on these variables. Not all individuals allocated to felodipine had their SBP reduced ,140 mmHg, and not all individuals receiving placebo had SBP .140 mmHg; therefore, the different outcome incidences refer to average rather than individual SBP values below or above 140 mmHg. Hypertensives with randomization SBP ,153 mmHg cannot be defined as grade 1 because at randomization FEVER patients were on low-dose hydrochlorothiazide (12.5 mg daily), and their untreated blood pressure was unknown. However, average SBP under very mild therapies was only 144 mmHg, and it is unlikely that a consistent part of these patients had more than a moderate BP elevation.
In all subgroups SBP means achieved under felodipine were only slightly ,140 mmHg, therefore the present analyses cannot shed light on a possible J-shaped relationship between achieved BP and outcomes, suggested by recent post hoc analyses of randomized trials, which are, at best, hypothesis generating. 30 Finally, this study included Chinese subjects only. This gives homogeneity to the trial, and provides evidence on stroke prevention in a population heavily contributing to stroke burden worldwide. These results can be extrapolated to Caucasian or African American patients only with reservations. The relationship between BP and stroke is steeper in Chinese than in Western populations, 31 and it is likely that in the latter a SBP difference .4 mmHg may be needed to obtain similar reductions in stroke. Stroke is one of the main causes of disease burden in Western populations also, and its reduction is one of the major benefits of antihypertensive therapy. Incidence of secondary outcomes (all cardiac events, death by any cause) was also significantly reduced in FEVER, 6 as well as in relevant subgroups analysed in this paper, thus indicating stroke prevention was not the only benefit of BP lowering, and this suggests that benefits of aiming at a SBP ,140 mmHg may be obtained in other population groups in the world. Throughout this paper, the benefits of more intense treatment have been attributed to the albeit small BP difference, in line with evidence from trial meta-analyses that the benefits of all antihypertensive agents are due to BP lowering. 13, 28 A specific contribution of felodipine cannot be excluded, however, especially since calcium antagonists may have a slightly greater effectiveness in stroke prevention than other agents, 28 and stroke was the most frequent outcome in our Chinese cohort.
Conclusions
These current analyses of FEVER give evidence of outcome reduction by targeting SBP ,140 mmHg in hypertensive patients at old age, or without diabetes, or without concurrent cardiovascular disease, or with neither diabetes nor cardiovascular disease, as well as in individuals with moderate initial elevation of blood pressure, thus providing well-needed support to the guidelines recommendation of a goal SBP ,140 mmHg in the elderly and uncomplicated hypertensive patients. The size of the benefit is greater in the elderly than in low-to-moderate-risk uncomplicated hypertensives, but even in the latter group it appears to justify the small and modestly expensive increment of drug therapy required in FEVER to achieve goal SBP. Analyses in patients with high risk, because of diabetes, previous cardiovascular disease and LVH, also support a SBP goal ,140 mmHg in these patients, but it remains open whether these high-risk patients may have greater benefit from even lower BP targets or run the risk of excessive BP reduction (J-shaped curve) because of a more elevated threshold for organ underperfusion. 1, 30 Although these analyses provide support, entirely missing so far, to the prudent recommendation to lower SBP ,140 mmHg in all hypertensive patients independently of their overall risk or baseline characteristics, they are subgroup analyses, a part of them are post hoc, and therefore require confirmation in prospectively planned trials.
